Pierre Fabre Medicament of France and Zambon S.p.A. of Italy have successfully executed an agreement, signed February 15, 2007, giving Pierre Fabre commercial rights to Zambon’s product portfolio in Germany.  The strategic partnership involves multiple products, including Panotile Cipro (anti-infective), Fluimicil (mucolytic), Monuril and Lorafem (antibiotics). Also, Pierre Fabre will retain Zambon’s medical sales force in Germany to strengthen its network in the country.  Pierre Fabre M...